Deep Track Capital Acquires Significant Stake in Verastem Inc: A Strategic Investment in Cancer Treatment

Wednesday, Nov 26, 2025 11:22 pm ET1min read

Deep Track Capital acquired a significant stake in Verastem Inc, a biopharmaceutical company developing novel anticancer agents, with a purchase of 7.7 million shares at $7.55 per share. This investment represents a 1.6% impact on Deep Track Capital's portfolio and positions Verastem Inc as a significant holding. Verastem Inc has faced challenges but demonstrated a 25.7% revenue growth over the past three years, with a focus on critical cancer treatment pathways.

Deep Track Capital Acquires Significant Stake in Verastem Inc: A Strategic Investment in Cancer Treatment

Comments



Add a public comment...
No comments

No comments yet